The Author(s) 2014. This article is published with open access at Springerlink.com Abstract Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with non-valvular atrial fibrillation (NVAF) and symptomatic venous thromboembolism (VTE). The ENGAGE AF-TIMI 48 study (N = 21,105; mean CHADS2 score 2.8) compared edoxaban 60 mg once daily (high-dose regimen) and edoxaban 30 mg once daily (low-dose regimen) with dose-adjusted warfarin [international normalized ratio (INR) 2.0–3.0] and found that both regimens were non-inferior to warfarin in the prevention ...
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patie...
BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The lo...
Background Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patien...
Vitamin K antagonists (VKAs) remain the standard therapy for anticoagulation in prevention and treat...
Vitamin K antagonists (VKAs) remain the standard therapy for anticoagulation in prevention and treat...
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a con...
Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for significant ...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
INTRODUCTION: Oral anticoagulation is central to the management of patients with atrial fibrillation...
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patie...
Vitamin K antagonists (VKA) and heparins have been utilized for the prevention and treatment of thro...
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patie...
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patie...
Oral anticoagulation therapy is the mainstay of stroke prevention in nonvalvular atrial fibrillation...
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patie...
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patie...
BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The lo...
Background Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patien...
Vitamin K antagonists (VKAs) remain the standard therapy for anticoagulation in prevention and treat...
Vitamin K antagonists (VKAs) remain the standard therapy for anticoagulation in prevention and treat...
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a con...
Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for significant ...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
INTRODUCTION: Oral anticoagulation is central to the management of patients with atrial fibrillation...
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patie...
Vitamin K antagonists (VKA) and heparins have been utilized for the prevention and treatment of thro...
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patie...
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patie...
Oral anticoagulation therapy is the mainstay of stroke prevention in nonvalvular atrial fibrillation...
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patie...
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patie...
BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The lo...
Background Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patien...